Genome-Scale Variant Interpretation

Automated Radiation Dose Estimation

Mission Statement

MutationForecaster® ( is Cytognomix’s patented web-portal for analysis of all types of mutations (coding and non-coding), including interpretation, comparison and management of genetic variant data. It’s a fully automated genome interpretation solution for research, translational and clinical labs.

MutationForecaster® combines our world-leading genome interpretation software on your exome, gene panel, or complete genome (Shannon transcription factor and splicing pipelines, ASSEDA, Veridical) with the Cytognomix User Variation Database and  Variant Effect Predictor.  With our integrated suite of software products, analyze coding, non-coding, and copy number variants, and compare new results with existing or your own database.  Select predicted mutations  by phenotype using articles with CytoVisualization Analytics.  With Workflows,  automatically perform end-to-end analysis with all of our software products.

Download an 1 page overview of MutationForecaster®link .

You can now experience our integrated suite of genome interpretation products through a free trial of MutationForecaster®. Once you register, analyze datasets that we have analyzed in our peer-reviewed publications with any of our software tools.

Ionizing radiation produces characteristic chromosome changes. The altered chromosomes contain two central constrictions, termed centromeres, instead of one (known as dicentric chromosomes [DCs]). Chromosome biodosimetry is approved by the IAEA for occupational radiation exposure, radiation emergencies, or monitoring long term exposures.  In emergency responses to a range of doses, labs need efficient methods that identify DCs.

Cytognomix has developed  a novel approach to find DCs that is independent of chromosome length, shape and structure from different laboratories (paper: TBME).  The Automated Dicentric Chromosome Identifier and Dose Estimator (ADCI) software  works on multiple platforms and uses images produced by any of the existing automated metaphase capture systems found in most cytogenetic laboratories. ADCI is now available for for trial or  purchase (link).  Or contact us for details (pricing).

ADCI* uses machine learning based algorithms with high sensitivity and specificity that distinguish monocentric and dicentric chromosomes (Try the Dicentric Chromosome Identifier web app). With novel image segmentation, ADCI has become a fully functional cytogenetic biodosimetry system. ADCI takes images from all types of commercial metaphase scanning systems,  selects high quality cells for analysis, identifies dicentric chromosomes (removing false positives), builds biodosimetry calibration curves, and estimates exposures.  ADCI fulfills the criteria established by the IAEA for accurate triage biodosimetry of a sample in less than an hour. The accuracy is comparable to an experienced cytogeneticist. Check out our online user manual: wiki.

We find and validate mutations that others cannot with advanced,  patented genomic  probe and bioinformatic technologies. Cytognomix continues our  long track record of creating technologies for genomic medicine. We anticipate and implement the needs of the biomedical and clinical genomics communities.

Additional Services

Browse the products section of the menu found in the header bar for more information regarding any of our services.

Latest Posts

December 10, 2013. Agreement to supply reagents for next generation sequencing

Cytognomix has agreed to provide hybridization enrichment products to the Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine at the Istituto Nazionale dei Tumori (INT), Fondazione IRCCS-Milan for sequencing of genes associated inherited neoplastic disease. The company’s scProbe design technology was selected by the INT because it provides […]

December 10, 2013. New patent on detecting biological exposure to radiation

US Patent 8,605,981, titled “Centromere detector and method for determining radiation exposure from chromosome abnormalities,” has been issued to Peter K.  Rogan, Joan H. Knoll, Jagath Samarabandu, and Akila Subasinghe. The patent is assigned to Cytognomix. The inventors have developed Automated Dicentric Chromosome Identifier (ADCI) software based on this technology. The present version of ADCI […]

January 20, 2013. Canadian Breast Cancer Foundation highlights Early Breast Cancer Detection project based on Cytognomix technology

The Canadian Breast Cancer Foundation has recognized our progress in developing novel next generation DNA sequencing and companion bioinformatic analysis technologies for early detection of breast cancer. See their profile at:  Canadian Breast Cancer Foundation article on Dr. Peter Rogan. Update January 20, 2013. CBCF has published a new  full profile of our project.

December 5, 2013. Breast Cancer Society of Canada Blog profiles our research

Stephanie Dorman published a method that improves the accuracy of a test commonly used in the genetic analysis of many types of cancers (Dorman et. al. Expanding probe repertoire and improving reproducibility in human genomic hybridization, Nucleic Acids Research, 41:e81, 2013). This technology was developed, supported and patented by Cytognomix. See:    The Breast Cancer […]

November 28. Presentation at the European Institute of Oncology

Dr. Peter Rogan is presenting at the European Institute of Oncology (IEO) Education Masterclass on 28 Nov in Milan, Italy. His talk is titled “Overview of bioinformatics tools for identification of new determinants of cancer risk.” sondraimcash advance loans no credit check no faxingloans to payday Brochure describing: Course at IEO 28_29 nov 2013 on inherited […]

November 11, 2013. Presentation at the University of Milan

On Monday, November 11 at 2 PM, Dr. Rogan will be presenting a seminar in the DIPARTIMENTO DI BIOTECNOLOGIE MEDICHE E MEDICINA TRASLAZIONALE (Medical Biotechnology and Translational Medicine) at the Universita degli Studi di Milano, titled: “Deciphering non-coding variants of uncertain significance in inherited and somatic breast cancer” check n cash loansno credit check no fax no employment […]

October 28, 2013. Presentation at the European Institute of Oncology

On October 30, Dr. Peter Rogan will be presenting; highest credit rating “New genetic variants in inherited and somatic breast cancer: clinical implications” at 12 PM IEO-Istituto Europeo di Oncologia, via Ripamonti 435, 20141 Milano. He will describe use of the Shannon pipeline and other tools to analyze mutations in inherited and somatic breast cancer. […]

October 25, 2013. Single copy FISH probes for metaphase epigenetic analysis

Since our presentation yesterday at the 2013 American Society of Human Genetics meeting, we have received several requests for information about our ab initio single copy FISH probes.  These FISH probes are only available from Cytognomix and  are the only products that can be used to detect differential accessibility in metaphase chromosomes.  No other company […]